Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Incyte

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities4.40%
Size of stake in company0.70%
Market capitalizationUSD 16.6 bn

Sector

Oncology

Main candidate

Jakafi

Main indications

Myelofibrosis

About the company

Incyte is a biotechnology company focused on the discovery and development of small-molecule drugs. Founded in 2002, the company is headquartered in the US with operations in Europe and Japan. The company´s leading drug, Jakafi, is marketed and used for the treatment of three indications (myelofibrosis, polycythemia vera, chronic graft-versus-host-disease). Incyte is marketing Jakafi in the US and its partner, Novartis, is marketing the product under the brand name Jakavi elsewhere in the world. Incyte´s other marketed drugs include Opzelura for Vitiligo, Olumiant for rheumatoid arthritis (partnered with Eli Lilly), Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. Incyte´s pipeline includes a broad range of drug candidates within oncology, dermatology, and other disease areas.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.